Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98


Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study.

Hamilton CA, Miller A, Casablanca Y, Horowitz NS, Rungruang B, Krivak TC, Richard SD, Rodriguez N, Birrer MJ, Backes FJ, Geller MA, Quinn M, Goodheart MJ, Mutch DG, Kavanagh JJ, Maxwell GL, Bookman MA.

Gynecol Oncol. 2018 Feb;148(2):275-280. doi: 10.1016/j.ygyno.2017.11.018. Epub 2017 Nov 28.


Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study.

Horowitz NS, Larry Maxwell G, Miller A, Hamilton CA, Rungruang B, Rodriguez N, Richard SD, Krivak TC, Fowler JM, Mutch DG, Van Le L, Lee RB, Argenta P, Bender D, Tewari KS, Gershenson D, Java JJ, Bookman MA.

Gynecol Oncol. 2018 Jan;148(1):49-55. doi: 10.1016/j.ygyno.2017.10.011. Epub 2017 Nov 23.


Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG study.

Ferriss JS, Java JJ, Bookman MA, Fleming GF, Monk BJ, Walker JL, Homesley HD, Fowler J, Greer BE, Boente MP, Burger RA.

Gynecol Oncol. 2015 Oct;139(1):17-22. doi: 10.1016/j.ygyno.2015.07.103. Epub 2015 Jul 26.


Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study.

Garcia-Soto AE, Java JJ, Nieves Neira W, Pearson JM, Cohn DE, Lele SB, Tewari KS, Walker JL, Alvarez Secord A, Armstrong DK, Copeland LJ.

Gynecol Oncol. 2016 Dec;143(3):484-489. doi: 10.1016/j.ygyno.2016.10.003. Epub 2016 Oct 7.


Who are the long-term survivors of high grade serous ovarian cancer?

Hoppenot C, Eckert MA, Tienda SM, Lengyel E.

Gynecol Oncol. 2018 Jan;148(1):204-212. doi: 10.1016/j.ygyno.2017.10.032. Epub 2017 Nov 8. Review.


Model for Prediction of Optimal Debulking of Epithelial Ovarian Cancer

Arab M, Jamdar F, Sadat Hosseini M, Ghodssi- Ghasemabadi R, Farzaneh F, Ashrafganjoei T.

Asian Pac J Cancer Prev. 2018 May 26;19(5):1319-1324.


What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study.

Rungruang BJ, Miller A, Krivak TC, Horowitz NS, Rodriguez N, Hamilton CA, Backes FJ, Carson LF, Friedlander M, Mutch DG, Goodheart MJ, Tewari KS, Wenham RM, Bookman MA, Maxwell GL, Richard SD.

Cancer. 2017 May 15;123(6):985-993. doi: 10.1002/cncr.30414. Epub 2016 Nov 16.


Preoperative serum CA125 levels do not predict suboptimal cytoreductive surgery in epithelial ovarian cancer.

Arits AH, Stoot JE, Botterweck AA, Roumen FJ, Voogd AC.

Int J Gynecol Cancer. 2008 Jul-Aug;18(4):621-8. Epub 2007 Sep 14.


A novel index for preoperative, non-invasive prediction of macro-radical primary surgery in patients with stage IIIC-IV ovarian cancer-a part of the Danish prospective pelvic mass study.

Karlsen MA, Fagö-Olsen C, Høgdall E, Schnack TH, Christensen IJ, Nedergaard L, Lundvall L, Lydolph MC, Engelholm SA, Høgdall C.

Tumour Biol. 2016 Sep;37(9):12619-12626. Epub 2016 Jul 20.


Clinical characteristics and prognostic inflection points among long-term survivors of advanced epithelial ovarian cancer.

Son JH, Kong TW, Paek J, Song KH, Chang SJ, Ryu HS.

Int J Gynaecol Obstet. 2017 Dec;139(3):352-357. doi: 10.1002/ijgo.12315. Epub 2017 Sep 28.


Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study.

Phippen NT, Secord AA, Wolf S, Samsa G, Davidson B, Abernethy AP, Cella D, Havrilesky LJ, Burger RA, Monk BJ, Leath CA 3rd.

Gynecol Oncol. 2017 Oct;147(1):98-103. doi: 10.1016/j.ygyno.2017.07.121. Epub 2017 Jul 23.


Clinical significance of ascites in epithelial ovarian cancer.

Huang H, Li YJ, Lan CY, Huang QD, Feng YL, Huang YW, Liu JH.

Neoplasma. 2013;60(5):546-52. doi: 10.4149/neo_2013_071.


Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.

Lane D, Matte I, Garde-Granger P, Laplante C, Carignan A, Rancourt C, Piché A.

BMC Cancer. 2015 Jul 1;15:492. doi: 10.1186/s12885-015-1511-7.


Associations between residual disease and survival in epithelial ovarian cancer by histologic type.

Melamed A, Manning-Geist B, Bregar AJ, Diver EJ, Goodman A, Del Carmen MG, Schorge JO, Rauh-Hain JA.

Gynecol Oncol. 2017 Nov;147(2):250-256. doi: 10.1016/j.ygyno.2017.08.003. Epub 2017 Aug 16.


Prognostic factors in ovarian carcinoma stage III patients. Can biomarkers improve the prediction of short- and long-term survivors?

Kaern J, Aghmesheh M, Nesland JM, Danielsen HE, Sandstad B, Friedlander M, Tropé C.

Int J Gynecol Cancer. 2005 Nov-Dec;15(6):1014-22.


Factors associated with cytoreducibility among women with ovarian carcinoma.

Eltabbakh GH, Mount SL, Beatty B, Simmons-Arnold L, Cooper K, Morgan A.

Gynecol Oncol. 2004 Nov;95(2):377-83.


The role of hyperthermic intraperitoneal chemotherapy using paclitaxel in platinum-sensitive recurrent epithelial ovarian cancer patients with microscopic residual disease after cytoreduction.

Cascales-Campos PA, Gil J, Feliciangeli E, Gil E, González-Gil A, López V, Ruiz-Pardo J, Nieto A, Parrilla JJ, Parrilla P.

Ann Surg Oncol. 2015 Mar;22(3):987-93. doi: 10.1245/s10434-014-4049-z. Epub 2014 Sep 12.


The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: a Gynecologic Oncology Group study.

Hamilton CA, Miller A, Miller C, Krivak TC, Farley JH, Chernofsky MR, Stany MP, Rose GS, Markman M, Ozols RF, Armstrong DK, Maxwell GL.

Gynecol Oncol. 2011 Sep;122(3):521-6. doi: 10.1016/j.ygyno.2011.04.041. Epub 2011 Jun 17.


Should stage IIIC ovarian cancer be further stratified by intraperitoneal vs. retroperitoneal only disease?: a Gynecologic Oncology Group study.

Rungruang B, Miller A, Richard SD, Hamilton CA, Rodriguez N, Bookman MA, Maxwell GL, Krivak TC, Horowitz NS.

Gynecol Oncol. 2012 Jan;124(1):53-8. doi: 10.1016/j.ygyno.2011.09.024. Epub 2011 Oct 26.


Supplemental Content

Support Center